Congress Wealth Management LLC DE lifted its stake in Insulet Co. (NASDAQ:PODD – Get Rating) by 10.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,883 shares of the medical instruments supplier’s stock after buying an additional 463 shares during the quarter. Congress Wealth Management LLC DE’s holdings in Insulet were worth $1,064,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Insulet by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 6,203,941 shares of the medical instruments supplier’s stock worth $1,652,668,000 after purchasing an additional 58,932 shares during the period. Clearbridge Investments LLC raised its holdings in Insulet by 38.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after purchasing an additional 474,545 shares during the period. Echo Street Capital Management LLC raised its holdings in Insulet by 60.8% in the 1st quarter. Echo Street Capital Management LLC now owns 802,434 shares of the medical instruments supplier’s stock worth $213,760,000 after purchasing an additional 303,355 shares during the period. William Blair Investment Management LLC acquired a new position in Insulet in the 1st quarter worth about $136,901,000. Finally, Rock Springs Capital Management LP raised its holdings in Insulet by 3.9% in the 1st quarter. Rock Springs Capital Management LP now owns 481,700 shares of the medical instruments supplier’s stock worth $128,320,000 after purchasing an additional 17,950 shares during the period.
Insulet Stock Up 1.0 %
Insulet stock opened at $292.63 on Thursday. Insulet Co. has a 1-year low of $181.00 and a 1-year high of $320.00. The company has a debt-to-equity ratio of 3.22, a current ratio of 3.98 and a quick ratio of 3.00. The stock has a market cap of $20.32 billion, a PE ratio of 1,219.29 and a beta of 0.79. The stock’s fifty day moving average is $256.02 and its two-hundred day moving average is $241.87.
Insider Buying and Selling at Insulet
Wall Street Analyst Weigh In
A number of equities analysts have commented on PODD shares. Canaccord Genuity Group increased their target price on Insulet from $290.00 to $310.00 and gave the company a “buy” rating in a report on Friday, November 4th. Robert W. Baird increased their target price on Insulet from $300.00 to $315.00 and gave the company an “outperform” rating in a report on Friday, November 4th. StockNews.com raised Insulet from a “sell” rating to a “hold” rating in a report on Wednesday, November 9th. Barclays initiated coverage on Insulet in a report on Monday, October 17th. They set an “equal weight” rating and a $238.00 target price for the company. Finally, Raymond James increased their price target on Insulet from $280.00 to $320.00 and gave the company an “outperform” rating in a report on Friday, November 4th. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $300.62.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
- Get a free copy of the StockNews.com research report on Insulet (PODD)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.